ArticleClinical case reports2026
Exudative Retinal Detachments: A Rare Adverse Effect of Topiramate.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topiramate-induced multifocal exudative retinal detachment is a rare but potentially vision-threatening adverse effect. We report a 59-year-old woman with idiopathic intracranial hypertension who developed painless bilateral blurry vision and color desaturation 8 days after initiation of topiramate 25 mg twice daily. Fundus examination and spectral-domain optical coherence tomography demonstrated bilateral multifocal exudative retinal detachment with subretinal fluid. Extensive infectious and inflammatory investigations were unremarkable. Topiramate was discontinued, resulting in complete anatomical resolution of subretinal fluid and improvement of visual acuity to 20/30 in both eyes over 3 months of follow-up. This case highlights the importance of recognizing this uncommon ocular complication and the potential for complete recovery following prompt drug cessation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.